Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Shares of biotech firm Ocugen OCGN.O rise 2.8% to $1.86 premarket

Co says it completed enrollment and dosing in a late-stage trial of OCU410ST for Stargardt disease, a rare inherited eye condition that causes gradual vision loss

Stargardt disease damages the retina — the light‑sensitive tissue at the back of the eye — and currently has no approved treatments

Co says the trial enrolled 63 patients, including children and adults, in under nine months

Main goal is to see if the one‑time eye injection can slow disease progression by reducing areas of retinal damage after one year - OCGN

Co says OCU410ST has shown a favorable safety profile so far, with no serious side effects reported

As of last close, stock up ~34% YTD